Obio Technology (Shanghai) Corp., Ltd. (688238.SS)
| Previous close | 6.69 |
| Open | 6.60 |
| Bid | 6.20 x N/A |
| Ask | 6.22 x N/A |
| Day's range | 6.20 - 6.65 |
| 52-week range | 4.78 - 13.83 |
| Volume | |
| Avg. volume | 9,900,229 |
| Market cap | 4.014B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
OBiO Technology will showcase at American Society of Gene & Cell Therapy
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th. 9 posters will be presented at American Society of Gene & Cell Therapy.
- PR Newswire
OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, officially announced an agreement with Refreshgene Therapeutics (Refreshgene). Under the agreement, OBiO leverages its capabilities of process development, large-scale cGMP commercial production and global business development to provide high-quality CDMO/CMO services and authorized cooperation services for Refreshgene's RRG-001 pipeline, and jo
